Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
News Medical7h
Novel therapeutic approaches targeting the Wnt pathway in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.
The Lancet12h
Non-invasive tests for assessing liver fibrosis and cirrhosis in chronic hepatitis B
Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...
Healio2d
Regimen may become new standard for relapsed/refractory diffuse large B-cell lymphoma
The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...
NHS to expand opt-out HIV and hepatitis testing
The NHS will automatically test patients for HIV, Hepatitis B and Hepatitis C unless they opt out at 90 hospitals.
precisionmedicineonline6d
FDA Clears Lion TCR to Begin Phase II Trial of TCR T-Cell Therapy in HBV-Related Liver Cancer
The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.
Up to 140,000 blood scandal relatives may claim compensation
As many as 140,000 bereaved parents, children and siblings of infected blood scandal victims may claim compensation under new ...